Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).
Thomas MeyerAndreas FunkeChristoph MünchDagmar KettemannAndré MaierBertram WalterAnnett ThomasSusanne SpittelPublished in: BMC neurology (2019)
THC:CBD is used in a wide dose range suggesting that the drug was applied on the basis of individual patients' needs and preferences. Contributing to this notion, moderate to severe spasticity was associated with an elevated number of daily THC:CBD actuations and stronger recommendation rate (NPS) as compared to patients with mild spasticity. Overall, treatment satisfaction (TSQM-9) was high. The results suggest that THC:CBD may serve as a valuable addition in the spectrum of symptomatic therapy in ALS. However, prospective studies and head-to-head comparisons to other spasticity medications are of interest to further explore the effectiveness of THC:CBD in the management of spasticity, and other ALS-related symptoms.
Keyphrases
- amyotrophic lateral sclerosis
- spinal cord injury
- botulinum toxin
- upper limb
- cerebral palsy
- end stage renal disease
- systematic review
- physical activity
- chronic kidney disease
- stem cells
- ejection fraction
- early onset
- prognostic factors
- high intensity
- optic nerve
- peritoneal dialysis
- sleep quality
- optical coherence tomography
- adverse drug
- patient reported